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Summary
The Ras signaling pathway allows cells to translate external
cues into diverse biological responses. Depending on con-
text and the threshold reached, Ras signaling can promote
growth, proliferation, differentiation, or cell survival. Failure
to maintain precise control of Ras can have adverse physio-
logical consequences. Indeed, excess Ras signaling
disrupts developmental patterning and causes develop-
mental disorders [1, 2], and in mature tissues, it can lead to
cancer [3–5]. We identify Rabex-5 as a new component of
Ras signaling crucial for achieving proper pathway outputs
in multiple contexts in vivo. We show that Drosophila
Rabex-5 restricts Ras signaling to establish organism size,
wing vein pattern, and eye versus antennal fate. Rabex-5
has both Rab5 guanine nucleotide exchange factor (GEF)
activity that regulates endocytic trafficking [6] and ubiquitin
ligase activity [7, 8]. Surprisingly, overexpression studies
demonstrate that Rabex-5 ubiquitin ligase activity, not its
Rab5 GEF activity, is required to restrict wing vein specifica-
tion and to suppress the eye phenotypes of oncogenic Ras
expression. Furthermore, genetic interaction experiments
indicate that Rabex-5 acts at the step of Ras, and tissue
culture studies show that Rabex-5 promotes Ras ubiquitina-
tion. Together, these findings reveal a new mechanism for
attenuating Ras signaling in vivo and suggest an important
role for Rabex-5-mediated Ras ubiquitination in pathway
homeostasis.
Results and Discussion
Rabex-5 Loss Causes Increased Size
We characterized the gene Rabex-5 (also called RabGEF1,
annotated CG9139; see Figure S1 available online) in
Drosophila. Rabex-5 was first identified as a Rab5 guanine
nucleotide exchange factor (GEF) with a highly conserved
VPS9 domain [6]. Studies of Rab5 and other VPS proteins
indicate that they play a role in growth control [9, 10]. We
used gal4/UAS expression [11] of an inverted repeat allele of
Rabex-5, Rabex-5IR [12], to perform tissue-specific RNA inter-
ference (RNAi), and we generated deletion alleles Rabex-5ex9,
Rabex-5ex40, andRabex-5ex42 (Figure S1; Supplemental Exper-
imental Procedures).
Deletion allele homozygotes, heterozygotes with one copy
of Rabex-5ex9,Rabex-5ex40, orRabex-5ex42 over the large dele-
tion Df(3L)BSC250, and flies undergoing strong, constitutive
Rabex-5 RNAi died as giant larvae or giant pupae, often con-
taining melanotic tumors (Figures 1A and 1B; data not shown).
Using RNAi conditions to reduce but not eliminate Rabex-5*Correspondence: cathie.pfleger@mssm.eduresulted in viable adults whose length, weight, and wing size
increased by over 10% (Figures 1C–1E).
Loss of Rabex-5 Causes Ectopic Wing Veins
and Eye/Antennal Effects
Constitutive or wing-specific Rabex-5 RNAi resulted in extra
posterior crossveins (PCV) and extra longitudinal veins (LV)
(Figures 1G and 1I–1K; Figure S1) compared to controls
(Figures 1F and 1H). Removing one copy ofRabex-5 enhanced
Rabex-5RNAi in thewing (Figure 1J), and homozygousRabex-
5ex42 mutant wing tissue also formed extra veins (Figure S1).
Thus, it is unlikely this phenotype resulted fromRNAi off-target
effects.
Strong Rabex-5 RNAi in the early eye led to 10%–25% of
eyes with severe phenotypes, including overgrown eyes,
outgrowths, small or lost eyes, and extra antennae (Figures
1M–1P; Figure S1), that were not observed in controls
(Figure 1L). Similar phenotypes were seen in eyes containing
primarily Rabex-5ex42 mutant tissue (Figure S1).
Rabex-5 Mutant Larvae Exhibit Increased ERK Activity
These phenotypes are consistent with failure to regulate Ras.
Increased Ras signaling causes melanotic tumors [13], as
seen upon loss of Rabex-5. Ras activity is required for wing
vein specification and, in excess, causes ectopic veins
[14, 15], as seen uponRabex-5 reduction. Ras is also important
in the eye. Increased Ras signaling early in eye development
induces hyperplastic growth [16], and exceeding certain
thresholds may promote antennal fates instead of eye fates
[17]. Eye phenotypes from Rabex-5 loss are consistent with
Ras activity near the threshold between driving hyperplasia
and promoting an eye-to-antenna switch. To evaluate Ras
signaling, we assessed dually phosphorylated ERK (dpERK),
a downstream Ras effector. Western analysis showed 2.5-
fold to 5-fold increased ERK activity in mutant larvae
compared to controls when normalized for total ERK
(Figure 1Q; Figure S1). Previous in vitro studies reported that
Rabex-5 loss in mast cells in culture extended the duration
of ERK activation when triggered by aggregation of Fc3R1
receptors or by stem cell factor [18, 19], consistent with our
in vivo findings.
Size, Eye, and Wing Phenotypes Are Ras Dependent
Ras mutations dominantly suppressed the extra wing veins
caused by constitutive and wing-specific Rabex-5 RNAi
(Figure 1K; Figure S1), reduced the percentage of flies with
severe eye phenotypes upon Rabex-5 RNAi (Figure 1P), and
suppressed the increased body size, body length, and wing
area of constitutive Rabex-5 RNAi (Figure 1D; Figure S1).
Body weight of all flies and wing area in female flies were no
longer statistically different from controls. Mutations in Egfr,
sos, Raf, MEK, and ERK dominantly suppressed the extra
PCV RNAi phenotype (Figure S1). Mutation in ERK also domi-
nantly suppressed homozygous Rabex-5ex42 phenotypes
(Figure S1).
These data indicate that Rabex-5 restricts Ras signaling
through ERK to achieve appropriate organism size, to specify
Genotype Body length Body weight Wing area
Actgal4/+ 1.000 ± 0.022(16) 1.000 ± 0.024(153) 1.000 ± 0.070(14)
Act>Rabex-5
IR 1.101 ± 0.028(15)* 1.113 ± 0.016(234)* 1.126 ± 0.023(13)*
Act>Rabex-5
IR
; Ras
e1b
/+ 1.080 ± 0.030(15)† 1.022 ± 0.064(111)† 1.042 ± 0.065(13)†
Genotype Extra PCV Extra LV
Actgal4/+ 1.6% (2/123) 0.0% (0/123)
Act>Rabex-5
IR 94.7% (36/38)* 18.4% (7/38)*
Act>Rabex-5
IR
; Ras
e1b
/+ 3.2% (1/31)† 0.0% (0/31)†
Act>Rabex-5
IR
; Ras
e2f
/+ 8.3% (3/36)† 0.0% (0/36)†
C765gal4/+ 0.0% (0/102) 0.0% (0/102)
C765>Rabex-5
IR 80.6% (116/144)* 73.6% (106/144)*
C765>Rabex-5
IR
; Ras
e1b
/+ 1.7% (1/58)† 0.0% (0/58)†
+/+ ex42/ex42 Actgal4/+ Act>Rabex-5IR
Genotype
Strong
eye/antennal
phenotypes
ey>dcr2/+ 0.0% (0/134)
ey>dcr2, Rabex-5
IR 20.7% (31/150)*
ey>dcr2, Rabex-5
IR
; Ras
e1b
/+ 8.8% (6/68)†
Act>Rabex-5IR
Actgal4/+
Actgal4/+ Act>Rabex-5
IR
c765gal4/+ c765>Rabex-5
IR
Rabex-5
ex42
/+;
c765>Rabex-5
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+/+    ex42/ex42
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Figure 1. Loss of Rabex-5 Causes Increased Size, Ectopic Wing Veins, and
Eye/Antennal Phenotypes
(A and B) FRT80B control, left. Homozygous Rabex-5 deletion (ex42/ex42)
resulted in giant larvae (A, right) and pupae (B, right), often containing mela-
notic masses (arrows, A).
(C) Constitutive Rabex-5 RNA interference (RNAi) (Act>Rabex-5IR, right)
increased adult size compared to Actgal4/+ controls (left, males shown).
(D) Table of Act>Rabex-5IR phenotypes. Length, weight, and wing area are
normalized to 1.000 for controls and are shown as a ratio to controls6 stan-
dard deviation; numbers of samples are in parentheses.
(E) Overlay of Act>Rabex-5IR (red) and control Actgal4/+ (blue) wings.
(F) Control Actgal4/+ wing.
(G) Act>Rabex-5IR wings contain extra posterior crossveins (PCV, bottom
arrow) and extra longitudinal veins (LV, top arrow).
(H) Control c765gal4/+ wing.
(I and J)Rabex-5RNAi in thewing at 30Cusing c765gal4 caused extra veins
(arrows, I) and was enhanced by deletion allele Rabex-5ex42 (J).
(K) Table of wing phenotypes. Wings with ectopic veins over total wings are
shown in parentheses.
(L) Control ey>dcr2 eye.
(M–O) Strong Rabex-5 RNAi in the early eye (ey>dcr2, Rabex-5IR) produced
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Drosophila.
Loss of Rabex-5 Enhances Activated Ras and Egfr
but Not Raf
If Rabex-5 restricts Ras signaling, mutations activating the
pathway in an otherwise wild-type background may be
somewhat inhibited by endogenous Rabex-5. Therefore, loss
of Rabex-5 might exacerbate the consequence of expressing
activated pathway components. Activated Egfr (EgfrA887T),
RasV12S35 (oncogenic Ras signaling primarily through ERK),
and Raf (Rafgof) [20] (details in Supplemental Experimental
Procedures) expression in differentiating eye cells each
caused rough eyes of reduced size (EgfrA887T, Figure 2A,
Figure S2; RasV12S35, Figure 2B, Figure S2; Rafgof, data not
shown). As these phenotypes worsened, we observed black
tissue and lethality (Figure S2). Loss of Rabex-5 significantly
enhanced the number of eyes with black tissue and sig-
nificantly increased lethality of EgfrA887T or RasV12S35
expression (Figures 2A–2C; Figure S2). Rabex-5 RNAi in differ-
entiating eye cells resulted in no obvious abnormalities
(Figure S2), so phenotypic enhancement was not likely due
to additive effects of combining two visible phenotypes. Unlike
its enhancement of EgfrA887T and RasV12S35 phenotypes,
reducing Rabex-5 in differentiating eye cells did not enhance
the phenotype of Rafgof expression (Figure 2C; data not
shown).
Expressing RasV12S35 in the early eye results in eye over-
growth and other abnormalities; loss of Rabex-5 dramatically
enhanced these phenotypes (Figures 2G and 2H; Figure S2),
notably the overgrowth, extra antennae, and ectopic eye
phenotypes in larval eye discs (Figures 2G and 2H;
Figure S2) compared to control discs (Figures 2D–2F).
The Ubiquitin Ligase Domain of Rabex-5 Restricts Wing
Vein Formation
Rabex-5 displays GEF activity for Rab5 [8]. Rab5 regulates
endocytosis and can influence receptor trafficking, so
Rabex-5 could inhibit Ras via Rab5. In addition, Rabex-5 has
a ubiquitin ligase domain [9, 10]. We engineered Drosophila
transgenic lines to express myc-tagged wild-type and mutant
forms of Rabex-5. Rabex-5DPYT was designed to inactivate
Rab5 GEF activity, and Rabex-5FY was designed to inactivate
ubiquitin ligase activity within full-length protein (Supple-
mental Experimental Procedures). Both Rabex-5WT and
Rabex-5DPYT expressed in the posterior wing resulted in loss
of crossveins and loss of the distal part of longitudinal vein
L5 (Figures 3B, 3C, and 3E; Figure S3) compared to a control
wing (Figure 3A). In contrast, Rabex-5FY did not alter wing
vein pattern (Figures 3D and 3E). These results indicate that
the ubiquitin ligase domain restricts wing vein formation.
Clones of Rabex-5DPYT in wing discs showed loss of dpERK
staining (Figures 3F–3H), establishing that wing vein loss likely
resulted from decreased Ras signaling.overgrown eyes (M), small eyes (N), extra antennae (O, overhead view of N)
and other abnormalities (Figure S1).
(P) Table of eye results. For tables in (D), (K), and (P), *p < 0.05 compared to
control; yp < 0.05 for suppression by Ras alleles. Images and quantitation
shown in (D)–(O) are from females; quantitation in (P) is of males.
(Q) Western blot of larvae homozygous for control FRT80B or Rabex-5ex42.
dpERK (top) and total ERK (bottom) staining showed 3.9-fold 6 0.23
(standard deviation) increased ERK activation in mutant larvae compared
to controls. Additional controls are shown in Figure S1.
Genotype
Eyes with
black tissue
GMRgal4/+ 0% (0/200)
GMR>Rabex-5
IR 0% (0/100)
GMR>Egfr
A887T 0% (0/68)
GMR> Egfr
A887T
, Rabex-5
IR 13% (4/32)*
GMR>RasV12S35 0% (0/100)
GMR>RasV12S35, Rabex-5
IR 37% (20/54)*
GMR>Raf
gof 40.4% (21/52)
GMR>Raf
gof
, Rabex-5
IR 37.5% (12/32)
   RasV12S35
RasV12S35     + Rabex-5
IR
               Egfr
A887T
   Egfr
A887T           
+ Rabex-5
IR
ey>RasV12S35
ey>RasV12S35
      + Rabex-5
IR
overgrown (more than twice the size of eygal4/+)
ectopic antennae
ectopic eyes
ey>RasV12S35 ey>RasV12S35,
Rabex-5IR
ey>Rabex-5IReygal4/+
A      C
B
H
D              E         
F               G  
Figure 2. Loss of Rabex-5 Enhances Activated
Egfr and Oncogenic Ras
(A–C) Activated Egfr, EgfrA887T (left, A), or
RasV12S35 (left, B) expressed in differentiating
eye cells caused small, rough eyes.
(A and B) Rabex-5 RNAi (right) enhanced
GMR>EgfrA887T (A) and GMR>RasV12S35 (B), as
evidenced by the appearance of black tissue
(arrows; enlarged in insets) and lethality
(Figure S2).
(C) Table quantifying effects of Rabex-5 loss on
EgfrA887T, RasV12S35, and Raf gof. Female eyes
are shown and quantified. In Raf gof eyes,
Rabex-5 reduction did not statistically signifi-
cantly change the frequency of black tissue
compared to control (p > 0.05).
(D–G) ELAV (green) stains presumptive photore-
ceptors; Distal-less (red) stains presumptive
antennae in larval discs.
(D) eygal4/+ control.
(E) ey>Rabex-5IR control.
(F) Larval disc expressing RasV12S35 in the early
eye.
(G) RasV12S35 discs with reduced Rabex-5
showed increased overgrowth, extra antennae
(arrowheads), and ectopic eyes (arrow). Scale
bar represents 200 mm.
(H) Graph quantifying phenotypes in (D) and (E).
For table in (C) and graph in (H), *p < 0.05
compared to control. Additional controls and
quantitation are shown in Figure S2.
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If Rabex-5 inhibits Ras, it could antagonize oncogenic Ras.
To assay suppression, we expressed RasV12S35 in differenti-
ating eye cells using conditions resulting in black tissue in 30%
of eyes. Rabex-5WT and Rabex-5DPYT each reduced rough-
ness, eye size, and black tissue phenotypes ofRasV12S35-ex-
pressing eyes (Figures 4A, 4B, and 4D; Figure S4). Change in
roughness was subtle; eyes were scored double blind by other
laboratory members to confirm suppression in an unbiased
manner. By quantitation, Rabex-5WT and Rabex-5DPYT statisti-
cally significantly suppressed the reduced eye size and black
tissue phenotypes compared to RasV12S35 eyes (Figure 4D;
Figure S4). Rescued eyes were statistically no different in
size from controls. Rabex-5FY did not suppress RasV12S35
phenotypes (Figures 4C and 4D; Figure S4). Consistent with
Figure 2C, Rabex-5WT did not suppress appearance of black
tissue in Rafgof eyes (Figure S4). Enhancement of RasV12S35
by Rabex-5 loss (Figure 2) and its suppression by the Rabex-
5 ubiquitin ligase domain (Figure 4), together with failure of
Rabex-5 to suppress the Rafgof phenotype and its loss to
enhance Rafgof (Figure 2; Figure 4; data not shown), indicate
that Rabex-5 restricts Ras signaling through its ubiquitin ligase
domain most likely at the step of Ras.
Rabex-5 Promotes Ras Ubiquitination
The importance of a functional ubiquitin ligase domain for Ras
inhibition suggests that ubiquitination of one or more
substrates mediates effects on Ras signaling. Previously, we
and others showed that Ras ubiquitination reduces Ras
signaling to ERK [21, 22]. In S2 cells, Rabex-5 promoted Ras
ubiquitination via its ligase domain (Figure 4E; Figure S4),
but, showing specificity for Ras, Rabex-5 did not promote
Rab5 ubiquitination (Figure S4). F25 Y26 mutation impairs
ubiquitin binding [7]; therefore, Rabex-5 could bind ubiquiti-
nated Ras to block downstream signaling or Rabex-5 mayaffect Ras by targeting other substrates. However, the
simplest model is that Rabex-5 constrains Ras signaling by
direct Ras ubiquitination. In fact, mammalian Rabex-5
promotes Ras ubiquitination in a purified system ([23], this
issue of Current Biology).
Conclusions
Our findings represent the first evidence that Rabex-5 attenu-
ates Ras signaling in vivo. We show that inhibition occurs at
the step of Ras possibly by direct Ras ubiquitination, and
such inhibition plays a critical role in control of size and tissue
fate in Drosophila. Mammalian Rabex-5 promotes ubiquitina-
tion of HRas and NRas [23], suggesting that Rabex-5 restric-
tion of Ras is highly conserved. Interestingly, we did not see
supernumary R7 cells upon Rabex-5 loss (data not shown),
indicating that Rabex-5 antagonizes Ras in some, but not all,
developmental contexts. Germline mutations increasing Ras
signaling occur in ‘‘Rasopathies’’ [1, 2], which are associated
with patterning defects, making Rabex-5 an attractive candi-
date to evaluate in developmental disorders. Indeed, Rabex-
5 wing vein phenotypes resemble those seen in a Drosophila
model of Noonan Syndrome [24]. Somatic mutations causing
higher Ras activity are common in cancer [3–5]. Rabex-5 over-
growth phenotypes resemble those of mutation in many
Drosophila tumor suppressors [25, 26]. Thus, our study
suggests that Rabex-5 ubiquitin ligase activity could serve
as a novel means of tumor suppression.
Experimental Procedures
Student’s unpaired t tests compared length, weight, wing area (Figure 1D),
and eye size (Figure 4D). Chi-square or Fisher’s exact tests compared PCV,
LV, or eye phenotypes (Figures 1K and 1P; Figures 2C and 2H; Figure 3E;
Figure 4D). S2 cells cultured at 25Cwere transfected with pIE1-4-Flag-6His-
Ras,Actin-Gal4,UAS-HA-Ubiquitin, andUAS-myc-Rabex-5 using Cellfectin
(Invitrogen). Ubiquitin conjugates were isolated from cell lysates as
described [21]. Flies were raised on standard media at 25C unless
Genotype
Partial to
complete
PCV Loss
Complete
PCV loss
Distal
L5 loss
engal4/+ (males) 0.0% (0/54) 0.0% (0/54) 0.0% (0/54)
engal4/+ (females) 0.0% (0/51) 0.0% (0/51) 0.0% (0/51)
en>Rabex-5
WT (males) 65.0% (13/20)* 0.0% (0/20) 15% (3/20)*
en>Rabex-5
WT (females) 57.9% (44/76)* 6.6% (5/76) 10.5% (8/76)*
en>Rabex-5
DPYT (males) 100% (11/11)* 9.1% (1/11) 45.5% (5/11)*
en>Rabex-5
DPYT (females) 83.3% (30/36)* 16.7% (6/36)* 11.1% (4/36)*
en>Rabex-5
FY (males) 0.0% (0/18) 0.0% (0/18) 0.0% (0/18)
en>Rabex-5
FY (females) 0.0% (0/20) 0.0% (0/20) 0.0% (0/20)
en>Rabex-5
WT
     en>Rabex-5
DPYT
        en>Rabex-5
FY
      engal4/+
            
             
 
A B              
C               D
E
F H  G
Figure 3. Rabex-5 Regulates Wing Vein Specification via Its Ubiquitin
Ligase Domain
(A) Control engal4/+ wing.
(B and C) Expressing Rabex-5WT (B) or Rabex-5DPYT (C) using engal4 re-
sulted in crossvein loss (arrows).
(D) Expressing Rabex-5FY did not alter wing vein pattern. Female wings are
shown.
(E) Table of results from (A)–(D). *p < 0.05 for transgenes compared to
control.
(F–H) Wing clones expressing Rabex-5DPYT (green) show loss of dpERK
staining (red in G and H, arrows in G).
(H) Merge of (F) and (G). Scale bar represents 50 mm. Additional controls are
shown in Figure S3.
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1381otherwise stated. Larvae were dissected, stained, and imaged as before
[21]. Extracts were prepared from individual larvae, and western blots
were visualized with the Li-Cor Odyssey as before [21]. For genotypes
and additional details, see the Supplemental Experimental Procedures.
Supplemental Information
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/j.
cub.2010.06.058.
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Genotype
Eyes with
substantial
black patches Eye size
GMRgal4/+ 0.0% (0/102) 1.000 ± 0.088(8)
GMR>Rabex-5
WT 0.0% (0/90) 0.938 ± 0.056(7)
GMR>Rabex-5
DPYT 0.0% (0/44) 0.944 ± 0.046(9)
GMR>Rabex-5
FY 0.0% (0/34) 0.967 ± 0.042(9)
GMR>RasV12S35 29.5% (23/78)* 0.919 ± 0.072(8)*
GMR>RasV12S35, Rabex-5
WT 19.3% (17/88)† 1.054 ± 0.039(8)†
GMR>RasV12S35, Rabex-5
DPYT 5.6% (6/108)† 1.022 ± 0.057(8)†
GMR>RasV12S35, Rabex-5
FY 70.8% (17/24)* 0.847 ± 0.086(8)*
RasV12S35           RasV12S35
        +Rabex-5
WT
            HA-Ub
FlagHisRas
Rabex-5
 -   +   +   +
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Figure 4. Rabex-5 Ubiquitin Ligase Domain Suppresses Oncogenic Ras
(A–C) CoexpressingRabex-5WT (A,RasV12S35+Rabex-5WT, right) orRabex-5DPYT (B,RasV12S35+Rabex-5DPYT, right) in differentiating eye cells suppressed
RasV12S35 (left in A–C).
(C) Coexpressing Rabex-5FY (RasV12S35+Rabex-5FY, right) did not suppress RasV12S35.
(D) Summary table. Eye size was normalized to 1.000 forGMRgal4/+ controls and is shown as a ratio to controls6 standard deviation. *p < 0.05 for Rabex-5
and/or RasV12S35 transgene expression compared to GMRgal4/+ control; yp < 0.05 for suppression of GMR>RasV12S35.
(E) Nickel pull-down of lysates from cells expressing tagged Ras, Ub, and Rabex-5. Rabex-5 expression increased Ras ubiquitination (right lane). Anti-HA
(top) and anti-FLAG (bottom) staining are shown. Diubiquitinated Ras is indicated by arrows; unconjugated Ras is indicated by an arrowhead. Additional
controls are shown in Figure S4.
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